Download PDF
Drug Res (Stuttg) 2023; 73(07): 378-387
DOI: 10.1055/a-2088-3718
Review

Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review

Navid Omidkhoda
1   Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
Sina Mahdiani
2   Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
Sara Samadi
1   Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
,
Hossein Rahimi
3   Department of Internal Medicine, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
,
Amir Hooshang Mohammadpour 
1   Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
4   Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Loads of new therapeutic regimes have been turned up to manage Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), particularly in elderly patients who are unfit for intensive chemotherapy. Despite accumulating research, the best MDS and AML management approach is indeterminate. Myelodysplastic syndrome implies a group of various hematopoietic stem cell disorders that may progress to acute myeloid leukemia. These disorders are more frequent in older adults. To the high rate of morbidity and abundant toxicities related to the therapeutic approaches, also, the treatment would be challenging. The clinical effectiveness of valproic acid, a histone deacetylase inhibitor, in MDS and AML patients is unknown, even though it has demonstrated positive activities to promote differentiation and apoptosis in cancer cells. We investigated the clinical research on the effects of valproic acid in conjunction with various drugs, including low-dose cytarabine, all-trans retinoic acid, DNA-hypomethylating agents, hydrazine, and theophylline. We conclude that VPA is a safe and effective treatment option for MDS and AML patients, particularly when used in conjunction with all-trans retinoic acid, DNA-hypomethylating drugs, and hydralazine. However, more randomized clinical studies are required to identify an ideal regimen.

Key words

valproic acid - myelodysplastic syndrome - acute myeloid leukemia


Publication History

Received: 27 December 2022

Accepted: 14 April 2023

Article published online:
23 May 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Cazzola M. Myelodysplastic Syndromes . N Engl J Med 2020; 383: 1358-1374
    CrossrefPubMedGoogle Scholar
  • 2 Grimwade D, Walker H, Oliver F. et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial . Blood, The Journal of the American Society of Hematology 1998; 92: 2322-2333
    PubMedGoogle Scholar
  • 3 Kantarjian H, Ravandi F, O'Brien S. et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia . Blood 2010; 116: 4422-4429
    CrossrefPubMedGoogle Scholar
  • 4 Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes . Semin Hematol 2008; 45: 23-30
    CrossrefPubMedGoogle Scholar
  • 5 Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation . New England Journal of Medicine 2003; 349: 2042-2054
    CrossrefPubMedGoogle Scholar
  • 6 Göttlicher M, Minucci S, Zhu P. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells . The EMBO journal 2001; 20: 6969-6978
    CrossrefPubMedGoogle Scholar
  • 7 Kuendgen A, Strupp C, Aivado M. et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid . Blood 2004; 104: 1266-1269
    CrossrefPubMedGoogle Scholar
  • 8 Lubbert M, Grishina O, Schmoor C. et al. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial . Journal of Clinical Oncology 2020; 38: 257 - +. 
    CrossrefPubMedGoogle Scholar
  • 9 Malcovati L, Hellström-Lindberg E, Bowen D. et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet . Blood 2013; 122: 2943-2964
    CrossrefPubMedGoogle Scholar
  • 10 List AF, Bennett JM, Sekeres MA. et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS . Leukemia 2014; 28: 1033-1040
    CrossrefPubMedGoogle Scholar
  • 11 Kantarjian H, Issa JP, Rosenfeld CS. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study . Cancer 2006; 106: 1794-1803
    CrossrefPubMedGoogle Scholar
  • 12 Fenaux P, Mufti GJ, Hellstrom-Lindberg E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study . Lancet Oncol 2009; 10: 223-232
    CrossrefPubMedGoogle Scholar
  • 13 Garcia-Manero G, Chien KS, Montalban-Bravo G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management . Am J Hematol 2020; 95: 1399-1420
    CrossrefPubMedGoogle Scholar
  • 14 Koreth J, Pidala J, Perez WS. et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis . Journal of clinical oncology 2013; 31: 2662
    CrossrefPubMedGoogle Scholar
  • 15 De Lima M, Giralt S, Thall PF. et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study . Cancer 2010; 116: 5420-5431
    CrossrefPubMedGoogle Scholar
  • 16 Kantarjian H, Kadia T, DiNardo C. et al. Acute myeloid leukemia: current progress and future directions . Blood cancer journal 2021; 11: 41
    CrossrefPubMedGoogle Scholar
  • 17 Bourin M, Chenu F, Hascoet M. The role of sodium channels in the mechanism of action of antidepressants and mood stabilizers . Current drug targets 2009; 10: 1052-1060
    CrossrefPubMedGoogle Scholar
  • 18 Felsenfeld G, Groudine M. Controlling the double helix . Nature 2003; 421: 448-453
    CrossrefPubMedGoogle Scholar
  • 19 Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention . Oncogene 2007; 26: 5310-5318
    CrossrefPubMedGoogle Scholar
  • 20 Fraga MF, Ballestar E, Villar-Garea A. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer . Nat Genet 2005; 37: 391-400
    CrossrefPubMedGoogle Scholar
  • 21 Nakagawa M, Oda Y, Eguchi T. et al. Expression profile of class I histone deacetylases in human cancer tissues . Oncol Rep 2007; 18: 769-774
    PubMedGoogle Scholar
  • 22 Richon VM, Emiliani S, Verdin E. et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases . Proc Natl Acad Sci U S A 1998; 95: 3003-3007
    CrossrefPubMedGoogle Scholar
  • 23 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action . Oncogene 2007; 26: 5541-5552
    CrossrefPubMedGoogle Scholar
  • 24 Blaheta RA, Nau H, Michaelis M. Valproate and valproate-analogues: potent tools to fight against cancer . Current Medicinal Chemistry 2002; 9: 1417-1433
    CrossrefPubMedGoogle Scholar
  • 25 Kuendgen A, Schmid M, Schlenk R. et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination moth all-trans retinoic acid in patients with acute myeloid leukemia . Cancer 2006; 106: 112-119
    CrossrefPubMedGoogle Scholar
  • 26 Grignani F, De Matteis S, Nervi C. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia . Nature 1998; 391: 815-818
    CrossrefPubMedGoogle Scholar
  • 27 Lin RJ, Nagy L, Inoue S. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia . Nature 1998; 391: 811-814
    CrossrefPubMedGoogle Scholar
  • 28 Ferrara FF, Fazi F, Bianchini A. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia . Cancer research 2001; 61: 2-7
    PubMedGoogle Scholar
  • 29 Kuendgen A, Knipp S, Fox F. et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia . Ann Hematol 2005; 84: 61-66
    CrossrefPubMedGoogle Scholar
  • 30 Bug G, Ritter M, Wassmann B. et al. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia . Cancer 2005; 104: 2717-2725
    CrossrefPubMedGoogle Scholar
  • 31 Pilatrino C, Cilloni D, Messa E. et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid . Cancer 2005; 104: 101-109
    CrossrefPubMedGoogle Scholar
  • 32 Cimino G, Lo-Coco F, Fenu S. et al. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia . Cancer Res 2006; 66: 8903-8911
    CrossrefPubMedGoogle Scholar
  • 33 Garcia-Manero G. Demethylating agents in myeloid malignancies . Current opinion in oncology 2008; 20
    PubMedGoogle Scholar
  • 34 Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B. et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia . Blood 2006; 108: 3271-3279
    CrossrefPubMedGoogle Scholar
  • 35 Blum W, Klisovic RB, Hackanson B. et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia . J Clin Oncol 2007; 25: 3884-3891
    CrossrefPubMedGoogle Scholar
  • 36 Issa JP, Garcia-Manero G, Huang X. et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia . Cancer 2015; 121: 556-561
    CrossrefPubMedGoogle Scholar
  • 37 Voso MT, Santini V, Finelli C. et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes . Clin Cancer Res 2009; 15: 5002-5007
    CrossrefPubMedGoogle Scholar
  • 38 Kuendgen A, Bug G, Ottmann OG. et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid . Clin Epigenetics 2011; 2: 389-399
    CrossrefPubMedGoogle Scholar
  • 39 Adès L, Duployez N, Guerci-Bresler A. et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations . British Journal of Haematology 2022; 198: 535-544
    CrossrefPubMedGoogle Scholar
  • 40 Garcia-Manero G, Gore SD. Future directions for the use of hypomethylating agents. in Seminars in hematology. Elsevier; 2005
    Google Scholar
  • 41 Estey EH, Thall PF, Pierce S. et al. Randomized phase II study of fludarabine+ cytosine arabinoside+ idarubicin±all-trans retinoic acid±granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome . Blood, The Journal of the American Society of Hematology 1999; 93: 2478-2484
    PubMedGoogle Scholar
  • 42 Alimena G, Morra E, Lazzarino M. et al. Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. 1988
    PubMed
  • 43 Di Croce L, Raker VA, Corsaro M. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor . Science 2002; 295: 1079-1082
    CrossrefPubMedGoogle Scholar
  • 44 Soriano AO, Yang H, Faderl S. et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome . Blood 2007; 110: 2302-2308
    CrossrefPubMedGoogle Scholar
  • 45 Raffoux E, Cras A, Recher C. et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome . Oncotarget 2010; 1: 34-42
    CrossrefPubMedGoogle Scholar
  • 46 Corsetti MT, Salvi F, Perticone S. et al. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C . Leuk Res 2011; 35: 991-997
    CrossrefPubMedGoogle Scholar
  • 47 Fredly H, Ersvær E, Kittang AO. et al. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia . Clinical Epigenetics 2013; 5: 01
    CrossrefPubMedGoogle Scholar
  • 48 Tassara M, Döhner K, Brossart P. et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients . Blood, The Journal of the American Society of Hematology 2014; 123: 4027-4036
    PubMedGoogle Scholar
  • 49 Ryningen A, Stapnes C, Lassalle P. et al. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid . Leuk Res 2009; 33: 779-787
    CrossrefPubMedGoogle Scholar
  • 50 Khanim FL, Bradbury CA, Arrazi J. et al. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML . British Journal of Haematology 2009; 144: 332-341
    CrossrefPubMedGoogle Scholar
  • 51 Candelaria M, Burgos S, Ponce M. et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS) . Annals of hematology 2017; 96: 1825-1832
    CrossrefPubMedGoogle Scholar
  • 52 Candelaria M, Herrera A, Labardini J. et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial . Ann Hematol 2011; 90: 379-387
    CrossrefPubMedGoogle Scholar
  • 53 Yang BH, Lin WZ, Chiang YT. et al. Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine . Front Oncol 2022; 12: 809014
    CrossrefPubMedGoogle Scholar
  • 54 Siitonen T, Timonen T, Juvonen E. et al. Leukemia, Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes. . Haematologica 2007; 92: 1119-1122
    CrossrefPubMedGoogle Scholar